The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
vertex partners with orna therapeutics to advance gene therapies for blood disorders
Vertex Pharmaceuticals has partnered with Orna Therapeutics, investing $65 million to develop next-gen gene therapies for sickle cell disease and transfusion-dependent beta thalassemia. This collaboration allows Orna to expand its research capabilities and leverage its lipid nanoparticle delivery technology, aiming to create accessible treatments that bypass traditional cell therapy limitations. Vertex's recent FDA approvals for gene therapies in these areas further enhance the significance of this partnership.
vertex partners with orna to advance in vivo gene editing therapies
Vertex Pharmaceuticals has entered a three-year partnership with Orna Therapeutics to advance in vivo gene therapies for sickle cell disease and beta thalassemia. The collaboration includes an upfront payment of $65 million, with potential milestone payments totaling up to $635 million. This initiative aims to enhance gene editing delivery methods, potentially eliminating the need for toxic preconditioning and streamlining the treatment process.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.